At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top France based CFO’ operating in the Health Care space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Sylvain Cascarino
CFO of Kurma Partners
More than 15 years of experience in Finance & Administration. Previously entrepreneur and CFO for Nekazen/Le MAG VoD. Fund controller & Internal Auditor for Jones Lang LaSalle. Tax Advisor with Arthur Andersen. Sylvain joined Kurma in January 2013.
Follow Sylvain Cascarino:
About Kurma Partners: Kurma Partners is a management company specializing in the financing of innovation in healthcare and biotechnology.
Thomas Gidoin
CFO of GenSight Biologics
Thomas Gidoin has been GenSight Biologics’ Chief Financial Officer since June 2015. From 2012 to mid-2015, Thomas was Vice President Finance at DBV Technologies S.A., where he led the Corporate Finance team and participated in public offerings and private placements, including the dual listing of DBV Technologies on the Nasdaq Global Select Market in 2014. From 2008 to 2011, he served in various positions at Ipsen S.A., including UK Operations Controller in London and Senior Financial Analyst in the Global Operations division in Paris. He started his career in audit at Ernst & Young. Thomas received a Master’s degree in International Finance from ESGF Paris and a Master’s degree in International Management from Neoma Business School in France.
Follow Thomas Gidoin:
About GenSight Biologics: GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.
Zina Hamoumi
CFO of Corwave
Zina Hamoumi brings more than 15 years of experience in corporate finance and accounting, including 7 years in the life sciences sector. She started her career at PwC in the audit practice, before moving to operational roles at Mexx (retail) and then Lundbeck France (pharmaceuticals), where she was Head of Finance and Logistics, overseeing financial operations that included sales, production, and R&D activities. She subsequently joined Victoria Beckham Ltd (fashion/retail) in London in 2014 as Finance Director. She supported the fast-growing business, put in place solid financial processes, and played an instrumental role in setting up a private equity round of funding. Zina holds a Msc in Management from EM Lyon business school.
Follow Zina Hamoumi:
About Corwave: CorWave is a medical device company developing innovative heart pumps.
David Auregan
Chief Financial Officer of Theraclion
David started his career with Arthur Andersen. David Auregan served from 2010 as Chief Financial Officer for EFESO Consulting (Alternext, ALEFE) where he helped to multiply the company’s value by 3 in 5 years. Previously, he worked as Financial Planning & Analysis Manager for Carrier and as Financial Analyst and Cash Flow Project Manager for GE Healthcare. David is a graduate of EDHEC and holds an MBA from Newcastle University. He is a certified Lean Six Sigma Black Belt.
Follow David Auregan:
About Theraclion: Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound.
Christelle Dumoussaud
Chief Financial Officer of ENTEROME
Christelle Dumoussaud has served as our Chief Financial Officer since 2015. Ms. Dumoussaud has more than 20 years’ experience in financial departments of various industries. In 2015, Ms. Dumoussaud served as General Secretary at Laboratoire Hepatoum-Dermophil Indien and Ms. Dumoussaud served as a financial consultant at Expert & Consult in 2014. From 2012 to 2013, Ms. Dumoussaud served as Administration and Finance Manager at Almavia and from 2007 to 2012, Ms. Dumoussaud served as General Secretary at Polygon/Munters France-Belgium. Ms. Dumoussaud worked at Fournier/Solvay Pharma from 1997 to 2007, serving as the Finance Director from 2005 to 2007. Ms. Dumoussaud served as the Chief Financial Officer of Fournier Pharma Belgium from 2001 to 2004. Ms. Dumoussaud holds a Master in Business Management from the ISC Paris.
Follow Christelle Dumoussaud:
About ENTEROME: Enterome is a clinical-stage company developing drugs for chronic medical conditions relating to abnormalities of bacterial composition.
Erwan Martin
Chief Financial Officer of CellNovo
Erwan brings over 20 years of experience in finance, biotechnology and corporate development. Before joining Cellnovo, Erwan was Chief Financial Officer of Genomic Vision (Euronext: GV), a position he had held since 2009. He was also VP of Corporate Development until 2015, undertaking financing operations such as the Company’s initial public offering. He has also worked at Syndex, and co-founded Cytomics Pharmaceuticals, a biotechnology company specialising in the discovery of new medicines.
Follow Erwan Martin:
About CellNovo: CellNovo is a medical device company developing a wireless therapeutic system for diabetic patients.
Evelyne Nguyen
Chief Financial Officer of NicOx
Evelyne Nguyen is a C-executive with 28 years of experience in various industries, among which 20 years in pharma & biotech. Mrs. Nguyen’s track record is in leading changes for business growth and transformation. She led major external acquisitions, and successfully conducted strategic alliances as well as business development projects across borders, mainly in the US, Europe and Asia. With senior financial background, she has consistently strengthened Finance-Accounting and IS systems at corporate level, as well as optimized the management and monitoring of performance, both for big and medium-sized organizations in the healthcare environment. Before joining Nicox in 2014, Mrs. Nguyen held several corporate roles at LFB (Laboratoire Français du Fractionnement et des Biotechnologies), respectively as CFO – Senior Vice President Finance and Strategy, then Executive Vice President Biomanufacturing. Within LFB, she was member of the Executive Committee, member of the Board of Directors for GTC (United States), and President of Mabgene (France). Previously, Mrs Nguyen worked at SAUR, a provider for environmental services, and at Bristol Myers Squibb, where she was involved in the post-merger integration of Bristol Myers and Squibb in France. Mrs Nguyen graduated from ISG (Institut Supérieur de Gestion) and Stanford University.
Follow Evelyne Nguyen:
About NicOx: Nicox is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.
Pascale d’Arbonneau
Chief Financial Officer of CARMAT
A graduate of the ESCP Europe business school, Pascale d’Arbonneau is a member of the Association nationale des directeurs financiers et de contrôle de gestion, (DFCG, the French association of financial and management control managers) and a lecturer at Paris Diderot University. Before joining CARMAT, Pascale d’Arbonneau was Executive Director of the Econocom International B.V. (EIBV) family office. She began her career in 1989 as an auditor at Coopers & Lybrand (now PWC) before entering the pharmaceutical industry as Head of Finance & IT France at Johnson & Johnson – MSD (1995-1999). She spent most of her career (1999-2016) at GlaxoSmithKline (GSK). She joined as Director, Head of Controlling & Finance Partnering, France at GlaxoWellcome, just before its merger with SmithKline Beecham, managing a team of 20 people working on the combination of the two companies. She then held a number of senior positions within the Group (Vice President & Finance Controller, Pharma Europe from 2006 to 2010, Vice President & Area Finance Director, Western Europe from 2010 to 2014) before becoming Vice President Compliance and Control Integration for all business units worldwide.
Follow Pascale d’Arbonneau:
About CARMAT: CARMAT is a medtech company, offering biocompatible, auto-regulated total artificial hearts as close as possible to the human heart.
Patrick Court
Chief Financial Officer of PathoQuest
Mr. Court held a number of CFO and COO positions in both operational and strategic roles. Most recently, from 2016 to 2019 he was CFO for Eveon, a medical device company, and Company Secretary for Arbiom, a green tech company. From 2012 to 2016 Mr. Court served as CFO and COO for Safe Orthopedics, a company which commercializes sterile implants and single-use instruments for spine surgery. During his tenure at Safe Orthopedics he also oversaw the management of the company’s U.S. subsidiary and supported two fundraising efforts. Prior to this Mr. Court was CFO for IntegraGen, a genomic services and molecular diagnostics company, joining the company in 2001 shortly after its inception. At IntegraGen he managed all financial, legal, governance, intellectual property and human resources aspects of the company, later also becoming responsible for managing the company’s operations (production, information systems). While at IntegraGen he was also responsible for the creation and management of the Company’s U.S. and German subsidiaries. Between 2001 to 2009 he supervised six fundraising efforts and also support the company’s IPO in 2010. Mr. Court’s roles and responsibilities have necessitated working with diverse groups of technicians, engineers and scientists. Previously, Mr. Court worked for fifteen years in the financial market sector, asset management and corporate insolvency and turnaround. Mr. Court is a graduate of the Institut Supérieur de Gestion (ISG) Business School and the ESCP-EAP European School of Management.
Follow Patrick Court:
About PathoQuest: PathoQuest is a biotech company developing NGS-based metagenomic tests for exhaustive identification of pathogens.
Dominique Destriez
Chief Financial Officer of Robocath
Graduated from HEC and holding a Phd in accountancy, Dominique DESTRIEZ started his career in international audit and management accounting within large companies afterwards. He then joined Nocibé, a french comestic group, as financial director and played an active role in the company’s growth from 1999 to 2004. For over 15 years, Dominique supports investment funds and their participations to achieve financial structuring, M&A, funds raising, international development and stock exchange listing.
Follow Dominique Destriez:
About Robocath: Robocath is a medical robotics start-up company.
Valerie Worrall
CFO of EOS Imaging
Valérie Worrall has over 20 years’ experience in Finance in the Healthcare industry. She had a long tenure with Novartis and worked in a number of their divisions. Her international career led her to the United States, South East Asia, Switzerland, Great Britain and France. Most recently, she was the CFO of Balt, a French medical device company. She joined EOS imaging in 2018 as the Chief Financial Officer. Valérie Worrall has a Masters in Management from HEC Paris.
Follow Valerie Worrall:
About EOS Imaging: EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology.
Olivier Vonet
Founder, CFO of Foobot
Olivier Vonet is an entrepreneur and CFO of AirBoxLab. Olivier has bathed in technology startups as well as high tech investment banking since business school.
Follow Olivier Vonet:
About Foobot: Foobot is an Indoor Air Quality Monitor to help people take control of their closest environment
Richard Cruse
CFO ,Finance Director & Founder of ProFactor Pharma
Richard Cruse is the CFO ,Finance Director & Founder at ProFactor Pharma Ltd.
Follow Richard Cruse:
About ProFactor Pharma: ProFactor Pharma provides commercialise and supply recombinant blood factors for the treatment of haemophilia.
Bertrand Devillers
CFO of Fermentalg
Bertrand Devillers is the chief financial officer of Fermentalg.
Follow Bertrand Devillers:
About Fermentalg: Fermentalg is engaged in the production of micro-algae for the agrifood, healthcare and energy markets.
Matthieu Plessis
CFO of Voluntis
Matthieu has 25 years of experience in various finance positions in the pharmaceutical, telecom and IT industries. Prior to joining Voluntis, he was CFO of eFront, a global financial software vendor. In this position, he successfully supported the group’s rapid growth as well as it’s finance and M&A operations. Previously, he worked for Glaxo and SFR-Cegetel. He is a graduate of ESSCA management school.
Follow Matthieu Plessis:
About Voluntis: Voluntis is a healthcare-related software company specialized in patient relationship management.
Nathalie Huitorel
Chief Financial Officer of GENFIT
Nathalie Huitorel is a graduate of the SKEMA Business School (School of Management in Lille, France). For 10 years she was Chief Financial and Administrative Officer for MS COMPOSITES, a company specializing in high-performance composite materials. She took part in listing a subsidiary of the French company FINUCHEM on the Stock Exchange and has led numerous mergers and acquisitions. She was appointed Chief Financial and Administrative Officer at GENFIT in October 2007, and oversees the accounting, management and human resources departments.
Follow Nathalie Huitorel:
About GENFIT: GENFIT is a late-stage biopharmaceutical company.
Henri Mazoyer
CFO of SpineVision
Henri Mazoyer currently serves SpineVision as chief financial officer. He has more than 20 years of experience in Financial Management for industrial and service companies. Henri has participated to the development of GEMALTO in various Finance positions in Germany, France and Asia-Pacific Singapore before joining CROWN in Paris. His manufacturing background had been reinforced with a significant experience in services as Finance Director of ISCOOL ENTERTAINMENT, where he managed several fund raisings and participated to a successful IPO of the company in 2010. Prior to joining SpineVision, he provided assistance and guidance as part time CFO to innovative companies.
Follow Henri Mazoyer:
About SpineVision: SpineVision is a spinal technology company focused on the development and marketing of implants and instrumentation for spinal treatment.
Valentin Delahaye
Co-Founder & CFO of Enovap
Follow Valentin Delahaye:
About Enovap: Enovap is a intelligent dual-tank e-cigarette, designed and built to help smokers and vapers get full control of their nicotine intake.
Fabrice Kilfiger
Chief Financial Officer of Medicrea
Fabrice Kilfiger is the chief financial officer at Medicrea.
Follow Fabrice Kilfiger:
About Medicrea: Medicrea is a fully-dedicated spinal implant company focused on introducing reliable and innovative technologies to the global marketplace.
Sebastien Robitaille
Chief of Staff and Interim Chief Financial Officer of DBV Technologies
Sébastien Robitaille serves as Chief of Staff to the CEO and Deputy Chief Financial Officer, responsible for overseeing the global collective success drivers for the Company, leading the transformation from a development-stage biotechnology company to a potential commercial organization. He oversees Finance and Information Systems at Group level, and is a member of the Executive Committee. Mr. Robitaille brings extensive experience in the pharmaceutical industry and deep knowledge of performance management, forecasting and business modelling, transformation programs and implementation of strategic information systems. Mr. Robitaille joined DBV in 2015 as Senior Vice President, Group Controller & Information Systems and was subsequently named Deputy Chief Financial Officer. Prior to DBV, he worked at Ipsen for 15 years where he held various roles of increasing responsibility and participated in the company’s IPO. Mr. Robitaille received his Bachelor’s Degree in Business Administration-Finance from Paris School of Business.
Follow Sebastien Robitaille:
About DBV Technologies: DBV Technologies focuses on the development of innovative products for the diagnosis and treatment of food allergies.
Stanislas leonard Malmezat
Chief Financial Officer of Domain Therapeutics
Stanislas is Doctor of Pharmacy and is a graduate from the ESSEC Business School. He joined Domain Therapeutics in January 2018 as CFO to develop and structure the financial department as well as to assist the CEO in fund raising and strategic development. After his MBA, Stanislas began his career in the pharmaceutical industry as Product Manager at Johnson & Johnson. He built a strong experience in corporate finance while working in a French Venture Capital fund specialized in Biotechnology then as consultant in the Corporate Restructuring & Transaction Services department of Ernst & Young and later at Duff & Phelps Paris in Merger and Acquisition operations. He developed extensive operational background during more than 6 years as CFO at Rarecells Diagnostics and later at CleveXel Pharma.
Follow Stanislas leonard Malmezat:
About Domain Therapeutics: Domain Therapeutics develops small molecules targeting G-coupled protein receptors.
Baptiste Billoir
Co-Founder and CFO of AgenT
Follow Baptiste Billoir:
About AgenT: AgenT develops the first blood diagnosis to detect Alzheimer’s years before the onset of the irreversible symptoms.
Laurent Doire
Chief Financial Officer of motion recall
Follow Laurent Doire:
About motion recall: the expert in natural interactivity for Virtual and Mixed Reality